Bengaluru: Shilpa Medicare Ltd. delivered an impressive set of financial results for the first quarter of FY27, reporting strong growth in net profit and operating earnings. The pharmaceutical company benefited from improved operational performance, resulting in higher profitability and a modest expansion in EBITDA margin.
The Q1 FY27 performance reflects the company’s continued focus on high-value pharmaceutical products, contract development and manufacturing (CDMO) services, and active pharmaceutical ingredients (APIs).
Shilpa Medicare Q1 FY27 Financial Highlights
Shilpa Medicare reported a consolidated net profit of ₹100 crore in Q1 FY27, compared with ₹47 crore in the corresponding quarter last year. This represents a robust 112.8% year-on-year increase, making it one of the company’s strongest quarterly profit performances in recent years.
The company’s EBITDA increased to ₹136 crore from ₹91.6 crore in Q1 FY26, registering an impressive 48.5% year-on-year growth.
Shilpa Medicare EBITDA Margin Improves
Operating profitability also strengthened during the quarter.
EBITDA margin expanded to 29.3%, compared with 28.51% in the same quarter last year, reflecting an improvement of 79 basis points.
The higher margin indicates better cost management, improved product mix, and stronger operating leverage as the company scaled up its business.
Profit Growth Outpaces Operating Earnings
While EBITDA recorded healthy growth of nearly 49%, net profit more than doubled on a year-on-year basis.
The sharp rise in the bottom line suggests that, in addition to stronger operating performance, factors such as lower finance costs, tax efficiency, or other non-operating income may have supported overall earnings. Investors will look to the detailed financial statements for a clearer understanding of the drivers behind the significant profit growth.
Business Outlook
Shilpa Medicare continues to strengthen its presence across oncology products, APIs, formulations, biologics, and CDMO services. The company has also been expanding its global footprint by supplying pharmaceutical products to regulated and emerging markets.
Going forward, investors will focus on:
– Growth in the CDMO business.
– Demand for oncology and specialty pharmaceutical products.
– Regulatory approvals in key export markets.
– New product launches.
– Sustainability of operating margins.
The long-term outlook remains positive as global pharmaceutical companies increasingly outsource manufacturing and development activities to specialized Indian firms.
Conclusion
Shilpa Medicare delivered an excellent start to FY27, with consolidated net profit surging 112.8% year-on-year to ₹100 crore and EBITDA rising 48.5% to ₹136 crore.
The improvement in EBITDA margin to 29.3% further highlights the company’s stronger operational efficiency. If Shilpa Medicare maintains this momentum and continues expanding its specialty and CDMO businesses, it could be well-positioned for sustained earnings growth in the coming quarters.
Also see
United Breweries Q1 FY27 Results: Profit Slips 8% Despite Higher Revenue; EBITDA Margin Narrows